Our observations indicate that pharmacological activation of AMPK and antioxidants targeting Nox4 may represent a relevant therapeutic intervention to reduce IL-6- and IL-8-induced inflammation and cell invasion in RCC. This evidence concerns the gene IL6 and renal cell carcinoma.